Young blood transfusions show promise for reversing age-related cognitive decline in animal studies, but human trials remain inconclusive and the FDA warns against unproven commercial treatments.
Scientists are developing cellular reprogramming techniques using Yamanaka factors to reverse biological aging at the molecular level. While mouse studies show promising results, human applications face delivery challenges, safety concerns, and equity questions that could reshape society.
Loading featured articles...